Polaryx Therapeutics, Inc. SEC filings PLYX
Polaryx Therapeutics, Inc. has 35 filings in SEC EDGAR's recent list, going back to Aug 5, 2025. Its latest annual report, Form ARS, was filed on Jul 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Jul 28, 2026 | — |
| DEF 14A | Proxy statement | Jul 28, 2026 | Sep 10, 2026 |
| S-8 | Employee stock plan registration | Jul 24, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Jul 21, 2026 | Jul 19, 2026 |
| 8-K |
Current report
Other events
|
Jul 17, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | May 28, 2026 | May 27, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 28, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 24, 2026 | Dec 31, 2025 |
| 4 | Insider transaction | Feb 20, 2026 | Feb 18, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 5, 2026 | — |
| 424B4 | Prospectus | Feb 2, 2026 | — |
| EFFECT | Filing | Jan 29, 2026 | — |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 29, 2026 |
| CERT | Filing | Jan 28, 2026 | — |
| 8-A12B | For registration of certain classes | Jan 27, 2026 | — |
| S-1/A | Amended registration statement | Jan 27, 2026 | — |
| S-1/A | Amended registration statement | Jan 14, 2026 | — |
| S-1 | Registration statement | Nov 21, 2025 | — |
| C-U | Filing | Oct 31, 2025 | — |
| C-U | Filing | Oct 27, 2025 | — |
| C/A | Filing | Oct 1, 2025 | — |
| DRS/A | Filing | Sep 19, 2025 | — |
| C | Filing | Sep 3, 2025 | — |
| DRS | Filing | Aug 5, 2025 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PLYX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Paramus, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2075320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.